A breakthrough brain scan shows Parkinson’s drugs can misfire in the brain, helping some patients less than others. The fix?

Ambroxol, long used for coughs in Europe, stabilized symptoms and brain-damage markers in Parkinson’s dementia patients over ...

Researchers are using an advanced brain imaging method called MEG to understand why Parkinson’s drug levodopa doesn’t work ...

Groundbreaking research by Sydney University found a new brain protein involved in Parkinson’s disease and a way to modify it ...

The results of experiments in mice models were "astounding," said biochemist Suzanne Pfeffer of Stanford University.

In a breakthrough study, scientists found that silencing a single overactive enzyme in the brain reversed early damage caused ...

Currently dopamine replacement medications, like levodopa and dopamine agonists, are the primary treatment for Parkinson's ...

Some 25 years ago, a young Parkinson's disease investigator, Robert Hauser, MD, stepped to the podium at an American Academy ...

Simon Fraser University researchers are using a new approach to brain imaging that could improve how drugs are prescribed to ...

A cancer immunotherapy may slow Parkinson’s disease by blocking the spread of harmful brain proteins, Johns Hopkins researchers found.

Ambroxol chaperones GCase; in a previous study of people with Parkinson's disease, the drug led to increased GCase levels. It ...

A 12-month clinical trial investigated whether a cough medicine used in Europe called Ambroxol can slow dementia in people with Parkinson’s.